Xeris Biopharma Holdings, Inc. filings document the company’s commercial biopharmaceutical operations, financial results and governance as a Nasdaq-listed issuer. Its Form 8-K reports furnish quarterly and annual operating results, business highlights, financial guidance and product-related updates for Recorlev®, Gvoke® and Keveyis®.
The filing record also includes disclosure of Recorlev patent litigation under the Hatch-Waxman Act, involving Orange Book-listed patents and ANDA-related challenges. Proxy materials cover board composition, executive compensation, equity awards, shareholder voting matters and governance practices, while current reports document board changes and compensatory arrangements.
Xeris Biopharma Holdings, Inc. (XERS) Chief Financial Officer Steven Pieper sold 5,000 shares of Common Stock on October 1, 2026, at a weighted average price of $9.4073 per share. The sale was made under a Rule 10b5-1 trading plan adopted on August 18, 2025; prices in the multiple transactions ranged from $9.210 to $9.670, inclusive. Pieper directly held 1,351,053 shares after the sale.
Xeris Biopharma Holdings, Inc. (XERS) President and Chief Operating Officer Kevin McCulloch sold 15,000 common shares on October 1, 2026, at a weighted average price of $9.408 per share. The sale was made under a Rule 10b5-1 trading plan adopted September 4, 2025. McCulloch directly held 1,599,208 shares following the sale. A separate 25,000-share holding by his spouse was reported indirectly; McCulloch disclaimed beneficial ownership except to the extent of his pecuniary interest.
Xeris Biopharma Holdings, Inc. Chief Legal Officer and Corporate Secretary Beth Hecht sold 16,666 shares on October 1, 2026. The shares were sold in multiple transactions at a weighted average price of $9.4079 per share, with prices ranging from $9.180 to $9.680. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by Beth Hecht on August 8, 2025. She reported 1,111,130 shares held directly following the sale.
Xeris Biopharma Holdings, Inc. officer Beth Hecht reported an intended sale of 16,666 common shares, with an aggregate market value of $159,326.96 and an approximate sale date of October 1, 2026, through Morgan Stanley Smith Barney LLC. Her listed prior three-month sales include 16,666 shares on September 1, 2026, and 16,666 shares on August 3, 2026, each identified as a 10b5-1 sale.
At Xeris Biopharma Holdings, Inc. (XERS), President and Chief Operating Officer Kevin McCulloch sold 25,000 common shares at $10 per share on September 28, 2026, under a Rule 10b5-1 trading plan adopted September 4, 2025. He directly held 1,614,208 shares after the sale. The report also lists 25,000 shares held indirectly by his spouse; McCulloch disclaims beneficial ownership except to the extent of his pecuniary interest.
Xeris Biopharma Holdings, Inc. officer Kevin McCulloch reported a proposed sale of 70,000 common shares, with an aggregate market value of $637,000. Shares outstanding were 182,320,306 as of September 28, 2026. The shares were acquired upon vesting of restricted stock units from January 31, 2024, through January 31, 2025. The past-three-months section lists 10b5-1 sales by Kevin K. McCulloch of 15,000 shares on September 1, 2026, 15,000 shares on August 3, 2026, and 90,000 shares on July 1, 2026.
Xeris Biopharma Holdings, Inc. (XERS) outlined a comprehensive clinical and commercial plan for XP-8121, its investigational once-weekly subcutaneous levothyroxine for hypothyroidism. The Phase 3 registrational study, Cornerstone, is expected to start by year-end 2026, enrolling 500 well-controlled adults and adolescents across more than 50 U.S. sites for 54 weeks, with a 15% non-inferiority margin and greater than 90% statistical power versus daily oral levothyroxine. Additional Capstone (pediatric) and Touchstone (inconsistent-control) studies, plus real-world evidence work, are planned to support broad use. Xeris estimates 3–5 million treated U.S. hypothyroid patients remain inadequately controlled and states XP-8121 could reach $1–3 billion in peak net revenue if approved, with potential FDA approval and U.S. launch anticipated in 2030.
Xeris Biopharma Holdings, Inc. (XERS) reported that President and Chief Operating Officer Kevin McCulloch sold 15,000 shares of common stock on September 1, 2026 at a weighted average price of $8.4872 per share, pursuant to a Rule 10b5-1 trading plan adopted on September 4, 2025. Following this sale, he directly holds 1,639,208 shares of common stock and has indirect holdings of 25,000 shares held by his spouse, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
Xeris Biopharma Holdings, Inc. (XERS) insider Beth Hecht, Chief Legal Officer and Corporate Secretary, reported selling 16,666 shares of common stock on 2026-09-01 in an open-market transaction under a Rule 10b5-1 trading plan adopted on 2025-08-08. The weighted average sale price was $8.4864 per share, from multiple trades between $8.390 and $8.600. Following this sale, Hecht directly holds 1,127,796 shares of XERS common stock.